Granules India shares hit 52-week high as Q1 net profit jumps 181% to ₹134 crore

Granules India’s consolidated net profit surged over 181% YoY to ₹134.65 crore from ₹47.89 crore in Q1FY24. Sequentially, the company’s net profit grew nearly 4% QoQ from ₹129.65 crore in the March quarter of FY24.

The pharmaceutical company’s total revenue from operations for the June quarter of FY25 grew nearly 20% to ₹1,179.9 crore against ₹985.52 crore in Q1FY24. However, on a sequential basis, the company’s revenue from operations almost remained flat compared to ₹1,175.8 crore in Q4FY24.

Earnings before interest, taxes, depreciation, and amortisation (EBITDA) for Q1FY25 surged 89% YoY to ₹259.3 crore compared to ₹136.8 crore in Q1FY24. The company’s EBITDA margin increased to 22% in the June quarter compared to the same quarter a year ago.

After robust net profit growth in the first quarter of the current fiscal year, shares of Granules India closed 7.29% higher at ₹631.9 apiece on the NSE, extending gains for the ninth straight day.

The pharma stock has rallied nearly 28% in the last one month and 52% in the past six months. Shares of Granules India have gained nearly 95% in the past one year.

Granules India’s revenue share from North America increased to 74% in the June quarter from 61% in Q1FY24. The company posted a net debt of ₹79.41 in Q1FY25.

Granules India is a leading pharmaceutical company headquartered in Hyderabad. Its product portfolio includes Active Pharmaceutical Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Finished Dosages (FD).